Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients

被引：23

作者：

Yu, Dianke ^{[2
,3
]}

Shi, Juan ^{[4
]}

Sun, Tong ^{[5
,6
]}

Du, Xiaoli ^{[7
]}

Liu, Li ^{[4
]}

Zhang, Xiaojiao ^{[4
]}

Lu, Chao ^{[4
]}

Tang, Xiaohu ^{[4
]}

Li, Meng ^{[4
]}

Xiao, Lingchen ^{[4
]}

Zhang, Zhouwei ^{[4
]}

Yuan, Qipeng ^{[1
,4
]}

Yang, Ming ^{[1
,4
]}

机构：

[1] Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing 100029, Peoples R China

[2] Chinese Acad Med Sci, State Key Lab Mol Oncol, Dept Etiol & Carcinogenesis, Canc Inst & Hosp, Beijing 100730, Peoples R China

[3] Peking Union Med Coll, Beijing 100021, Peoples R China

[4] Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing, Peoples R China

[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[6] Harvard Univ, Sch Med, Boston, MA USA

[7] NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA

来源：

TUMOR BIOLOGY | 2012年 / 33卷 / 03期

基金：

中国国家自然科学基金;

关键词：

Chemotherapy; ERCC1; Meta-analysis; Pharmacogenetics; Platinum; NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; POLYMORPHISMS; CISPLATIN; SURVIVAL; XPD; ENDONUCLEASE; METAANALYSIS; ASSOCIATION; EXPRESSION;

D O I：

10.1007/s13277-011-0314-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The excision repair cross-complementation group 1 (ERCC1) plays an essential role in DNA repair and has been linked to resistance to platinum-based anticancer drugs among advanced non-small cell lung cancer (NSCLC) patients. We systematically evaluate whether ERCC1 Asn118Asn and C8092A genetic variants are associated with treatment response of platinum chemotherapy. We preformed a meta-analysis using ten eligible cohort studies (including 11 data-sets) with a total of 1,252 NSCLC patients to summarize the existing data on the association between the ERCC1 Asn118Asn and C8092A polymorphisms and response to platinum regiments. Odds ratio or hazard ratio with 95% confidence interval were calculated to estimate the correlation. We found that neither ERCC1 C8092A polymorphism nor Asn118Asn variant is associated with different response of platinum-based treatment among advanced NSCLC patients. Additionally, these two genetic variants are not related to treatment response in either Caucasian patients or Asian patients. Our meta-analysis indicates that the ERCC1 Asn118Asn and C8092A polymorphisms may not be good prognostic biomarkers for platinum-based chemotherapy in patients with stage III-IV NSCLC.

引用

页码：877 / 884

页数：8

共 50 条

[31] Expression of ERCC1, MSH2 and PARP1 in Non-small Cell Lung Cancer and Prognostic Value in Patients Treated with Platinum-based Chemotherapy [J].

Xie, Ke-Jie ;

He, Hong-Er ;

Sun, Ai-Jing ;

Liu, Xi-Bo ;

Sun, Li-Ping ;

Dong, Xue-Jun .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (06) :2591-2596

[32] Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta-Analysis [J].

Sito, Hilary ;

Sharzehan, Mohamad Ayub Khan ;

Islam, Md Asiful ;

Tan, Shing Cheng .

BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2024, 81

[33] ERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapy [J].

Ozdemir, Ozer ;

Ozdemir, Pelin ;

Veral, Ali ;

Uluer, Hatice ;

Ozhan, Mustafa Hikmet .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (08) :4679-4683

[34] Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer [J].

He, Caiyun ;

Duan, Zhipeng ;

Li, Ping ;

Xu, Qian ;

Yuan, Yuan .

ANTI-CANCER DRUGS, 2013, 24 (03) :300-305

[35] Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients [J].

Zhou, Fei ;

Yu, Zhuang ;

Jiang, Tao ;

Lv, Hongying ;

Yao, Ruyong ;

Liang, Jun .

SWISS MEDICAL WEEKLY, 2011, 141

[36] Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer [J].

Sito, Hilary ;

Tan, Shing Cheng .

MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)

[37] Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy [J].

Sullivan, Ivana ;

Salazar, Juliana ;

Majem, Margarita ;

Pallares, Cinta ;

del Rio, Elisabeth ;

Paez, David ;

Baiget, Montserrat ;

Barnadas, Agusti .

CANCER LETTERS, 2014, 353 (02) :160-166

[38] ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy [J].

Zhang, H. ;

Li, J. ;

Zhang, Y. ;

Sun, M. ;

Zhao, P. ;

Zhang, G. ;

Jin, C. ;

Sun, L. ;

He, M. ;

Wang, B. ;

Zhang, X. .

GENETICS AND MOLECULAR RESEARCH, 2014, 13 (04) :10215-10222

[39] Expression of ERCC1 and class III β-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy [J].

Zhang, Shucai ;

Li, Qi ;

Zhang, Quan ;

Wang, Jinghui ;

Zhang, Haiqing ;

Zhang, Zongde ;

Wang, Qunhui ;

Yang, Xinjie ;

Cu, Yanfei ;

Zhang, Hui .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2010, 25 (03) :141-149

[40] Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer [J].

Spasic, Jelena ;

Cavic, Milena ;

Stanic, Nemanja ;

Zaric, Bojan ;

Kovacevic, Tomi ;

Radosavljevic, Davorin ;

Nagorni-Obradovic, Ljudmila .

DOSE-RESPONSE, 2022, 20 (02)

← 1 2 3 4 5 →